$HUN

Huntsman Non-GAAP EPS of $0.04 misses by $0.03, revenue of $1.72B beats by $110M (HUN:NYSE)

Huntsman Corporation reported Q3 Non-GAAP EPS of $0.04, missing estimates by $0.03, but revenue of $1.72B exceeded expectations by $110M, up 17.8% year-over-year. Adjusted EBITDA rose to $132M from $94M in the prior year period, according to the company.

Original reporting
Published Nov 2, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HUN
Neutral
high confidence
Mentioned
$HUN
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$HUNNeutralHigh
01

Why it matters

The earnings release provides fresh data for valuation models and may trigger short‑term price adjustments.

02

Market read

First‑time disclosure of Q3 results; investors will reassess earnings expectations and sector positioning.

03

What to watch

Management commentary on cost controls and future guidance was not provided, leaving uncertainty about margin trends.

Relevance 8/10Novelty 8/10Timing: after‑hours release today

Background

Huntsman Corporation released its Q3 2026 earnings, reporting a slight EPS miss but a solid revenue beat.

Company-level read

Ticker impact

$HUNNeutralHigh confidence
Context

Q3 2026 Non‑GAAP EPS of $0.04 missed expectations by $0.03 while revenue of $1.72 B beat estimates by $110 M.

Expected impact

potential modest downside as the EPS miss outweighs the revenue beat

Evidence & confidence

Investors typically weigh earnings per share more heavily than revenue; a miss on EPS often triggers short‑term selling.

Market effects

Chemicals sector may see slight re‑rating as peers compare earnings beats versus misses.

U.S. market may see minor pressure on related specialty chemicals stocks.

Limited; impact confined to Huntsman and its immediate peers.

Counterpoint

Revenue beat could signal underlying demand strength; investors might view the EPS miss as a one‑off accounting issue.

Key entities

  • Huntsman Corporation

    U.S. specialty chemicals producer (ticker HUN).

Related articles

$HUNMed

Huntsman Q3 Earnings Call Highlights

Huntsman (HUN) reported Q3 earnings, noting seasonal slowing and higher raw-material costs in North American MDI markets. The company expects 2027 industry MDI growth to be flat to 2% and sees growth opportunities in advanced materials and automotive applications. Huntsman generated $82M in free cash flow in Q3 and anticipates substantial cash inflow in Q4. Europe remains challenging due to high energy costs, while China's market shows stability.

$HUNMed

Huntsman Corp (HUN) (Q3 2026) Earnings Call Highlights: $100 Million EBITDA Boost

Huntsman Corp (HUN) reported a $100M EBITDA boost in Q3 2026, with CEO Peter Huntsman expressing confidence in meeting $300M synergy targets from the Olin merger. He discussed market positioning, cost management, and growth expectations, including GDP-plus growth in Advanced Materials through 2027. The company expects to cover its dividend and capex with operating cash flow, despite minimal cash flow in the first nine months.

$HUNMedAI 8/10

Huntsman: Q3 Earnings Snapshot

Huntsman Corp. (HUN) reported a Q3 loss of $18M, or 10 cents per share, missing analyst expectations of 7 cents per share. Adjusted earnings were 4 cents per share. Revenue was $1.72B, exceeding forecasts of $1.6B.